Cargando…
Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns
Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This stu...
Autores principales: | Resende, Heloísa M., Ladislau, Leandro, Cardoso, Ana Carolina F., Brandão, Juliana Dinéia P., Assis, Biazi R., Cardoso, Paola, Marassi, Pedro Henrique A., Castilho, Vivienne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457873/ https://www.ncbi.nlm.nih.gov/pubmed/34415791 http://dx.doi.org/10.1200/GO.20.00649 |
Ejemplares similares
-
Sentinel lymph node biopsy using single-agent mapping tracer (blue
dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer
patients. Real world evidence
por: Resende, Heloisa Magda, et al.
Publicado: (2021) -
Biosimilars 101: considerations for U.S. oncologists in clinical practice
por: Camacho, Luis H, et al.
Publicado: (2014) -
Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil
por: de Assis, Marcos Renato, et al.
Publicado: (2018) -
What do oncologists need to know about biosimilar products?
por: Leung, Linda K. S., et al.
Publicado: (2016) -
Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)